



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

August 13, 2021

Tillman U. Gerngross, Ph.D.  
Chief Executive Officer  
Adagio Therapeutics, Inc.  
303 Wyman Street, Suite 300  
Waltham, MA 02451

**Re: Adagio Therapeutics, Inc.**  
**Registration Statement on Form S-1**  
**Exhibit Nos. 10.5, 10.6, 10.7 and 10.8**  
**Filed July 16, 2021, as amended**  
**File No. 333-257975**

Dear Dr. Gerngross:

On August 5, 2021, we concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance